2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174219
    BT-33 2999743-86-9
    BT-33 is a fuorinated macrobicyclic oxepanoprolinamide antibiotic with broad-spectrum activity against multidrug-resistant bacterial pathogens.
    BT-33
  • HY-174224
    Amb929 438196-25-9
    Amb929 (ZINC000002782982), a nsp3 ligand, is an anti-SARS-CoV-2 agent. Amb929 inhibits SARS-CoV2-mNG replication in VeroE6 cells with an EC50 of 34.7 µM. Amb929 has limited and moderate cytotoxicity for VeroE6 cells (CC50: 281 µM). Amb929 also inhibits SARS-CoV-2-mNG replication in Human Airway Epithelium (HAE).
    Amb929
  • HY-17422B
    Acyclovir monophosphate 66341-16-0 98%
    Acyclovir monophosphate is a potent anti-herpes simplex virus (HSV) agent. Acyclovir monophosphate blocks DNA synthesis through the inhibition of the viral DNA polymerase and terminates the chain elongation of the viral DNA. Acyclovir monophosphate shows antitumor activity.
    Acyclovir monophosphate
  • HY-17422C
    Acyclovir alaninate 84499-64-9 98%
    Acyclovir alaninate (Acyclovir alaninate) is a prodrug of Acyclovir (HY-17422) and can be used in antiviral (HSV) research.
    Acyclovir alaninate
  • HY-174233
    PROTAC SARS-CoV-2 Mpro degrader-4 98%
    PROTAC SARS-CoV-2 Mpro degrader-4 (Compound LLP019) is a SARS-CoV-2 MPro PROTAC degrader with a DC50 value of 4.7 μM. PROTAC SARS-CoV-2 Mpro degrader-4 induces MPro ubiquitination and proteasomal degradation to inhibit SARS-CoV-2 replication. PROTAC SARS-CoV-2 Mpro degrader-4 is promising for research of COVID-19 and related coronavirus infections.
    PROTAC SARS-CoV-2 Mpro degrader-4
  • HY-174235
    Thalidomide-OCH2-amide-PEG2-C2-Boc 2827750-18-3
    Thalidomide-OCH2-amide-PEG2-C2-Boc is an E3 ligase ligand-linker conjugate containing a cereblon (CRBN) ligand for E3 ubiquitin ligase and a linker. Thalidomide-OCH2-amide-PEG2-C2-Boc can be used to synthesize PROTAC SARS-CoV-2 Degrader-1 (HY-174233).
    Thalidomide-OCH2-amide-PEG2-C2-Boc
  • HY-174263
    PaFabV-IN-1
    PaFabV-IN-1 (Compound 3e) is a selective Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (PaFabV) inhibitor with an IC50 value of 0.25 μM. PaFabV-IN-1 is promising for research of infections caused by P. aeruginosa and other Gram-negative bacteria.
    PaFabV-IN-1
  • HY-174269
    HIV Capsid-IN-2
    HIV Capsid-IN-2 (Compound IC-2b4) is a potent HIV-1 capsid protein (CA) inhibitor. HIV Capsid-IN-2 shows inhibitory effects against both HIV-1 (EC50=0.08 μM) and HIV-2. HIV Capsid-IN-2 exerts inhibitory effects during both early and late stages of infection by directly and stably binding to HIV-1 CA.
    HIV Capsid-IN-2
  • HY-174273
    Antibacterial agent 280
    Antibacterial agent 280 (Compound 7af) is an antibacterial agent targeting methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA). Antibacterial agent 280 is promising for research of is promising for research of S. aureus infections.
    Antibacterial agent 280
  • HY-17430R
    Amprenavir (Standard) 161814-49-9 98%
    Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.
    Amprenavir (Standard)
  • HY-17431R
    Fosamprenavir Calcium Salt (Standard) 226700-81-8
    Fosamprenavir Calcium Salt (GW433908G) (Standard) is the analytical standard of Fosamprenavir Calcium Salt (HY-17431R). This product is intended for research and analytical applications. Fosamprenavir Calcium Salt (GW433908G) is an orally active inhibitor targeting HIV-1 protease and is a prodrug of Amprenavir (HY-17430). Fosamprenavir Calcium Salt is hydrolyzed into Amprenavir (VX-478) by cell phosphatases in the intestinal epithelium. Amprenavir binds to the active site of HIV-1 protease, preventing the processing of viral gag and gag-pol polyprotein precursors, thereby inhibiting the formation of mature infectious virus particles and exerting anti-HIV-1 infection activity. Fosamprenavir Calcium Salt can be used for the study of human immunodeficiency virus (HIV-1) infection.
    Fosamprenavir Calcium Salt (Standard)
  • HY-174342
    ELQ-453
    ELQ-453 is an inhibitor targeting the Qo site of the Plasmodium falciparum cytochrome bc1 complex (CytB) with an IC50 value of 0.57 nM. ELQ-453 blocks the mitochondrial function of the parasite, and suppresses Plasmodium infection in mosquitoes. ELQ-453 is promising for research of malaria.
    ELQ-453
  • HY-174343
    ELQ-121 1228283-36-0 98%
    ELQ-121 is a potent inhibitor of the ubiquinol-oxidation (QO)-site of parasites. ELQ-121 has IC50 of 0.05 nM against chloroquine sensitive and multidrug resistant P. falciparum in vitro. ELQ-121 inhibits T. gondii and N. caninum with IC50 below 1 nM in vitro. ELQ-121 suppresses B. besnoiti tachyzoite proliferation with an IC50 of 0.49 nM and induces mitochondrial disruption. ELQ-121 can form polyethylene glycol carbonate ester prodrug which demonstrates in vivo efficacy against P. yoelii in mice. ELQ-121 is suitable for antimalarial research.
    ELQ-121
  • HY-174350
    CK2-IN-15
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases.
    CK2-IN-15
  • HY-174370
    MePT-S-N-Pme 852301-66-7
    MePT-S-N-Pme is an inhibitor of SARS-CoV-2 RdRp activity. MePT-S-N-Pme demonstrates a significant reduced reporter activity with an IC50 of 7 μM in HEK 293 cells. MePT-S-N-Pme has a slight inhibitory effect on nucleotidyltransferase activity. MePT-S-N-Pme significantly inhibits SARS-CoV-2 replication in vitro.
    MePT-S-N-Pme
  • HY-174373
    SARS-CoV-2-IN-113 455304-63-9
    SARS-CoV-2-IN-113 (Compound 24) is a sulfonohydrazide derivative against SARS-CoV-2 infection with an IC50 of 8.320 μM. SARS-CoV-2-IN-113 exerts potent antiviral effects by inhibiting the entry and replication of SARS-CoV-2, and downregulating the expression of genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 has high selectivity and low cytotoxicity, and can be used in the research of SARS-CoV-2.
    SARS-CoV-2-IN-113
  • HY-17442R
    Azathramycin (Standard) 76801-85-9 98%
    Azathramycin (Azaerythromycin A) Standard is the analytical standard of Azathramycin (HY-17442). This product is intended for research and analytical applications. Azathramycin (Azaerythromycin A) is a methylated derivative of the antibiotic Azithromycin (HY-17506).
    Azathramycin (Standard)
  • HY-174459
    Anti-MRSA agent 31
    Anti-MRSA agent 31 (Compound 6) is an anti-methicillin-resistant Staphylococcus aureus (MRSA) agent with a MIC of 97 μg/mL and a MBC of 781.25 μg/mL. Anti-MRSA agent 31 has a potent antibacterial activity and a strong Binding Protein 2a (PBP2a) inhibitory activity.
    Anti-MRSA agent 31
  • HY-17460B
    Garenoxacin mesylate 223652-82-2 98%
    Garenoxacin (BMS 284756) mesylate is an orally active quinolone antibiotic and Garenoxacin mesylate has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes. Garenoxacin mesylate also inhibits Gyrase and TOPO IV.
    Garenoxacin mesylate
  • HY-17460R
    Garenoxacin (Standard) 194804-75-6
    Garenoxacin (Standard) is the analytical standard of Garenoxacin. This product is intended for research and analytical applications. Garenoxacin (BMS284756) is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms.
    Garenoxacin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity